Table 3. Five-year age-standardised prevalence (AP, per 100 000)a, age-standardised incidence rate (AI, per 100 000)a and 5-year relative survival (RS)b in the United States (SEER), Nordic Countries (NORDCAN), Italy (AIRTUM), Australia, and France with differences (Δ%) in comparison with the corresponding estimates in the United States. WOMEN, all ages.

		Nordic Countries		Italy		Australia		France
Site (ICD10)	United States		Δ%		Δ%		Δ%		Δ%
All cancers excluding non-melanoma
AP	1320	1117	−15	1233	−7	1242	−6	1094	−17
AI	409	351	−14	351	−14	380	−7	314	−23
RS	64%	59%	−7	61%	−4	64%	0	60%	−6
Oesophagusc (C15)
AP	3	2	−20	2	−32	—	−	2	−22
AI	2	2	0	1	−47	—	−	2	−2
RS	20%	13%	−35	13%	−35	—	−	15%	−23
Stomach (C16)
AP	10	10	1	25	160	10	6	10	7
AI	5	6	27	13	165	6	18	6	13
RS	30%	23%	−21	35%	18	25%	−15	31%	4
Colon and rectum (C18–C21)
AP	142	124	−13	135	−5	157	10	108	−24
AI	43	39	−10	41	−5	49	13	35	−19
RS	67%	60%	−10	60%	−10	62%	−7	59%	−12
Liver (C22)
AP	4	2	−49	9	108	3	−30	3	−26
AI	3	3	−19	7	126	2	−39	3	−12
RS	12%	8%	−37	16%	29	10%	−16	10%	−16
Pancreas (C25)
AP	8	6	−23	8	−3	7	−18	6	−29
AI	9	9	−3	9	−1	8	−16	6	−38
RS	7%	5%	−35	9%	29	5%	−33	7%	5
Trachea, bronchus, and lung (C33–C34)
AP	82	38	−53	29	−64	38	−53	22	−73
AI	50	27	−46	18	−64	26	−48	12	−76
RS	19%	14%	−27	17%	−10	14%	−25	17%	−11
Skin melanoma (C43)
AP	73	77	6	54	−26	168	131	47	−36
AI	16	16	5	11	−29	37	142	12	−22
RS	95%	90%	−4	88%	−7	94%	0	87%	−8
Breast (C50)
AP	532	483	−9	517	−3	488	−8	515	−3
AI	135	110	−19	116	−14	115	−15	122	−10
RS	91%	85%	−7	86%	−5	88%	−3	83%	−8
Cervix uteri (C53)
AP	27	39	44	30	11	25	−7	37	38
AI	8	10	26	7	−8	8	0	9	23
RS	65%	67%	2	57%	−13	72%	10	67%	2
Corpus uteri (C54)
AP	96	83	−13	72	−25	60	−37	56	−42
AI	25	20	−19	17	−32	15	−39	15	−41
RS	83%	83%	−1	77%	−8	82%	−2	73%	−13
Ovary (C56)
AP	38	48	24	37	−3	30	−21	35	−7
AI	14	16	17	13	−6	11	−20	12	−13
RS	39%	40%	1	38%	−3	40%	1	35%	−10
Kidney (C64–C66, C68)
AP	33	19	−41	30	−9	24	−28	22	−33
AI	9	7	−28	8	−11	7	−23	7	−22
RS	66%	55%	−17	68%	3	66%	0	63%	−4
Bladder (C67, D09.0, 30.3, 41.4)
AP	33	29	−12	34	4	13	−60	9	−73
AI	9	9	1	9	2	5	−44	3	−63
RS	80%	68%	−15	77%	−3	55%	−31	60%	−25
Brain (C70–C72)
AP	13	54	326	12	−5	10	−18	16	26
AI	6	14	162	6	9	5	−2	5	−12
RS	30%	23%	−23	27%	−11	13%	−57	19%	−37
Thyroid (C73)
AP	65	26	−60	83	28	43	−34	57	−12
AI	12	5	−63	14	14	8	−33	12	0
RS	95%	85%	−10	92%	−3	95%	0	90%	−5
Hodgkin lymphoma (C81)
AP	11	9	−23	15	34	8	−25	9	−18
AI	2	2	−21	3	25	2	−21	2	−11
RS	84%	86%	2	85%	1	86%	2	82%	−2
Non-Hodgkin lymphoma (C82–85, C96)
AP	57	37	−36	45	−22	49	−15	29	−49
AI	16	11	−31	13	−17	14	−7	10	−35
RS	69%	60%	−13	60%	−13	63%	−10	53%	−24
Multiple myelomac (C90)d
AP	12	10	−15	14	16	12	−1	12	−4
AI	4	4	−14	5	14	4	−2	4	−16
RS	37%	38%	3	46%	25	−	−	43%	17
Leukaemias (C91–C95)
AP	28	24	−16	22	−21	27	−5	23	−19
AI	9	8	−18	9	−4	9	−5	8	−13
RS	49%	61%	24	45%	−8	47%	−3	52%	6

^aStandardised on European population.

^bStandardised on the International Cancer Survival Standards.

^cUnavailable data are represented by ‘—'.

^dC88 is also included in Italy (4.0% of C88 and C90 cases in women).